US industry buoyed by Congress moves
This article was originally published in Clinica
US medical device makers are riding a fairly high wave in Congress at present, with Congress poised to finalise in a matter of weeks a bill that would solidify a five-year agreement allowing the Food and Drug Administration to collect user fees from the device industry in exchange for faster and more predictable product reviews. In addition, federal legislators are considering a substantial increase in the FDA's budget, including increases for review of medical devices.
You may also be interested in...
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.
In a surprise to the market, Dr Reddy’s and Hikma have prevailed in challenging six method-of-use patents shielding Amarin’s Vascepa in the US, opening the door for a potential at-risk launch that would likely be challenged by the originator.
Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.